Major US investment bank ratings are used to track the latest valuations and target prices on Wall Street daily, and to explore potential stock investment opportunities.

Hazard Warning:

Investing in small-cap stocks can be risky. Be prepared for potential liquidity challenges, high volatility, limited information, and financial instability. Always diversify your investments.

Today's Key Ratings and Concerns

Wedbush: Maintain SoundHound AI SoundHound AI(SOUN.US) ) rating at “Outperform,” raising price target to $16 from $15.

RBC Capital: Maintained Edgewise Therapeutics, Inc.(EWTX.US) ) rating at “Outperform,” raising the price target from $48 to $49.

RBC Capital: Maintained Nuvation Bio ( NUVATION BIO INC(NUVB.US) ) rating at “Outperform,” raising the price target from $6 to $7.

UBS: Maintains "Buy" rating on LifeStance Health Gr ( LIFESTANCE HEALTH GROUP, INC.(LFST.US) ), raising price target from $8.5 to $9.

Raymond James: Maintained a "strong buy" rating on Relay Therapeutics Relay Therapeutics(RLAY.US) ), lowering the price target from $29 to $19.

The symbol	Classification	Target price	Current price	Potential increase/decrease rate	(Classification) Agency
Edgewise Therapeutics, Inc.(EWTX.US)	to lift	$49.0	$12.68	286.44%	RBC Capital
NUVATION BIO INC(NUVB.US)	to lift	$7.0	$2.3	204.35%	RBC Capital
LIFESTANCE HEALTH GROUP, INC.(LFST.US)	to lift	$9.0	$4.37	105.95%	UBS
CLEANSPARK INC(CLSK.US)	to lift	$20.0	$10.07	98.61%	Macquarie
Verastem, Inc.(VSTM.US)	to lift	$13.0	$6.74	92.88%	RBC Capital
Relay Therapeutics(RLAY.US)	cut	$19.0	$3.22	490.06%	Raymond James
Ultragenyx Pharmaceutical, Inc.(RARE.US)	cut	$128.0	$27.54	364.78%	Canaccord Genuity
Trevi Therapeutics(TRVI.US)	cut	$27.0	$7.42	263.88%	Raymond James
Teads N.V.(TEAD.US)	cut	$5.0	$1.73	189.02%	JMP Securities

comments:
Target price unit and current price: US dollar;
Current Price: As of the latest closing price of US stocks;
Potential increase/decrease ratio = (Agency target price - current price) / current price 100% (Current price = last closing price up to the time of census)

For more detailed information about the classification, please refer to:

Lifting

HC Wainwright & Co.: Maintained a "Buy" rating on ANI Pharmaceuticals ANI Pharmaceuticals, Inc.(ANIP.US) ), raising the price target from $84 to $93.

Canaccord Genuity: Maintained a "Buy" rating on Artivion ( Artivion, Inc. Common Stock(AORT.US) ), raising the price target from $35 to $41.

Morgan Stanley: Maintained Arhaus, Inc.(ARHS.US) ) rating at "Market-Weight," raising the price target from $10 to $12.5.

Wedbush: Maintained an "Outperform" rating for Ascendis Pharma ( Ascendis Pharma A/S Sponsored ADR(ASND.US) ), raising the price target from $212 to $220.

RBC Capital: Maintained Ascendis Pharma ( Ascendis Pharma A/S Sponsored ADR(ASND.US) ) rating at “Outperform,” raising the price target from $210 to $230.

Citigroup: Maintained a "Buy" rating on Ascendis Pharma ( Ascendis Pharma A/S Sponsored ADR(ASND.US) ), raising the price target from $243 to $290.

Morgan Stanley: Maintained a “market-weight” rating on Celsius Holdings, Inc.(CELH.US) ), raising the price target from $42 to $56.

UBS: Maintains a "Buy" rating on Celsius Holdings, Inc.(CELH.US) ), raising the price target from $57 to $64.

Maxim Group: Maintained a "Buy" rating on Celsius Holdings, Inc.(CELH.US) ), raising the price target from $50 to $65.

Citigroup: Maintains a "Buy" rating on Celsius Holdings, Inc.(CELH.US) ), raising the price target from $55 to $60.

DA Davidson: Maintains Expedia Group Expedia Group(EXPE.US) "Neutral" rating, raises price target from $174 to $218.

Wedbush: Maintained a "Neutral" rating on Expedia Group ( Expedia Group(EXPE.US) ), raising the price target from $175 to $220.

UBS: Maintains a "Neutral" rating on Expedia Group ( Expedia Group(EXPE.US) ), raising the price target from $182 to $209.

RBC Capital: Maintains Expedia Group Expedia Group(EXPE.US) ) “Sector Match” rating, raises price target from $180 to $200.

UBS: Maintains a “Buy” rating on Flutter Entertainment ( Flutter Entertainment plc Ordinary Shares(FLUT.US) ), raising the price target from $340 to $360.

UBS: Maintains a "Neutral" rating on Warby Parker Warby Parker Inc.(WRBY.US) ), raising the price target from $20 to $23.

Macquarie: Maintained Wynn Resorts, Limited(WYNN.US) ) rating at "Outperform," raising the price target from $110 to $124.

RBC Capital: Maintain Block ( Block(XYZ.US) ) rating at “Outperform,” raising price target from $63 to $97.

Raymond James: Maintained an “Outperform” rating on YETI Holdings ( YETI Holdings(YETI.US) ), raising the price target from $34 to $37.

First coverage

nothing

reduction

RBC Capital: Maintained The Trade Desk(TTD.US) ) “Outperform” rating, lowered price target to $90 from $100.

Wedbush: Downgraded The Trade Desk(TTD.US) ) to "Neutral" with a price target cut from $90 to $68.

Citigroup: Downgraded The Trade Desk(TTD.US) ) to "Neutral", lowered the price target from $90 to $65.

Scotiabank: Maintains Trade Desk ( The Trade Desk(TTD.US) ) "Sector Match" rating, lowers price target to $60 from $83.

UBS: Maintains a “Buy” rating on Twilio ( Twilio, Inc. Class A(TWLO.US) ), lowers the price target from $150 to $135.

Scotiabank: Maintained Akamai(AKAM.US) ) rating at “Outperform,” lowered price target to $95 from $105.

RBC Capital: Maintained Amrize ( Amrize Ltd(AMRZ.US) ) rating at “Outperform,” lowered price target to $54 from $61.

RBC Capital: Maintained Arrowhead Pharma ( Arrowhead Pharmaceuticals, Inc.(ARWR.US) ) rating at “Outperform,” lowered price target from $40 to $38.

Canaccord Genuity: Maintained a "Buy" rating on Aspen Aerogels Inc(ASPN.US) ), lowering the price target from $11 to $10.

Ladenburg Thalmann: Downgraded Atmos Energy Corporation(ATO.US) ) to "Neutral", lowered the price target from $171 to $163.

UBS: Maintains a "Neutral" rating on Blend Labs, Inc.(BLND.US) ), lowers the price target from $4 to $3.5.

Editor's Note: This content was generated by Sahm's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risks, and securities prices may rise, fall, or even become worthless. Investing does not guarantee profits and may result in losses. Past performance does not necessarily reflect future performance. Before making any investment decision, investors should evaluate their financial situation, investment objectives, experience, and risk tolerance, and understand the nature of the investment products and the risks associated with them. For further details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, you are advised to seek independent professional advice.